1. Introduction and Meaning

Continuous Biomarker Accountability is an emerging concept in biomedical law, biotechnology regulation, medical ethics, health-data governance and clinical-trial accountability.

It refers to the continuing legal responsibility of healthcare institutions, pharmaceutical companies, biotechnology developers, diagnostic laboratories, researchers and digital-health platforms for the identification, measurement, interpretation, storage, monitoring and use of biomarkers throughout an individual's healthcare or research journey.

A biomarker is a measurable biological characteristic that provides information about a normal biological process, a disease process or a response to treatment.

Examples include:

Genetic biomarkers: BRCA1 and BRCA2 mutations.

Molecular biomarkers: Specific proteins, RNA and DNA alterations.

Blood biomarkers: Troponin, HbA1c and inflammatory markers.

Neurological biomarkers: Indicators associated with neurodegenerative disorders.

Pharmacological biomarkers: Indicators of drug response or toxicity.

Digital biomarkers: Physiological indicators collected through wearable devices and continuous monitoring technologies.

The concept of continuous accountability goes beyond the initial accuracy of a laboratory test. It requires institutions to remain accountable when biomarkers are repeatedly measured, updated, reinterpreted, transferred between healthcare providers or used to make consequential medical decisions.

Central legal proposition: A healthcare institution cannot necessarily discharge its responsibility merely by obtaining a biomarker result. Its responsibilities may continue through interpretation, clinical application, disclosure, data protection, correction of errors and subsequent monitoring.

Importantly, Continuous Biomarker Accountability is an emerging analytical framework rather than a universally recognised, independent legal doctrine.

2. Essential Elements of Continuous Biomarker Accountability

A. Accuracy and scientific validity

Biomarker testing must satisfy appropriate scientific and technical standards.

Legal accountability may arise where:

A diagnostic laboratory uses an inadequately validated test.

A biomarker result is incorrectly reported.

A healthcare provider relies on an unreliable biomarker.

A pharmaceutical company exaggerates the predictive value of a biomarker.

A diagnostic algorithm produces systematically inaccurate results.

The relevant responsibility depends on professional standards, statutory obligations, contractual duties and the circumstances of the case.

B. Continuous monitoring obligations

Some biomarkers change over time. A single measurement may become clinically outdated.

For example, a cancer patient's molecular profile may change following chemotherapy. A biomarker that previously indicated sensitivity to a particular drug may no longer provide the same predictive information.

Continuous accountability therefore raises questions concerning:

Frequency of repeat testing.

Clinical justification for monitoring.

Responsibility for detecting significant changes.

Communication of abnormal results.

Documentation of monitoring decisions.

Timely modification of treatment where medically justified.

Continuous monitoring does not mean compulsory or uninterrupted testing. Monitoring must be proportionate, clinically justified and consistent with informed consent.

C. Interpretation and clinical responsibility

A biomarker result is not necessarily equivalent to a medical diagnosis.

For example, a genetic predisposition may indicate increased disease risk without establishing that the individual currently suffers from the disease.

Healthcare professionals must distinguish between:

Diagnostic biomarkers.

Predictive biomarkers.

Prognostic biomarkers.

Pharmacodynamic biomarkers.

Susceptibility biomarkers.

Treatment-response biomarkers.

Incorrect interpretation can result in unnecessary treatment, delayed diagnosis, psychological injury or discrimination.

D. Data protection and confidentiality

Biomarker information may reveal highly sensitive information about an individual's health, genetic characteristics and familial disease risks.

Continuous accountability therefore requires safeguards concerning:

Collection and processing of biological information.

Patient consent and transparency.

Access controls.

Secure storage.

Data sharing with research institutions.

Commercial use of biomarker datasets.

Retention and deletion policies.

Prevention of unauthorised disclosure.

E. Reinterpretation and correction

Scientific knowledge evolves. A genetic variant initially classified as uncertain may subsequently be classified as pathogenic or benign.

This creates a difficult legal question: who is responsible for communicating a clinically significant reinterpretation?

Potentially responsible institutions may include the testing laboratory, treating hospital, genetic counsellor and research organisation, depending on their respective duties, contractual arrangements and continuing relationships with the patient.

A defensible accountability system should establish procedures for reviewing significant changes, correcting reports and communicating material findings.

3. Legal Framework in India

Continuous Biomarker Accountability can be analysed through several existing legal frameworks.

A. Constitutional protection

Article 21 provides the constitutional foundation for protecting an individual's bodily integrity, medical autonomy and privacy.

Article 14 becomes relevant when public authorities or state-controlled healthcare institutions make arbitrary decisions based on biomarker information.

For example, an individual should not be subjected to arbitrary exclusion from public healthcare merely because a genetic biomarker indicates a predisposition to a particular disease.

B. Digital personal data protection

Biomarker information maintained electronically can constitute personal data under the Digital Personal Data Protection Act, 2023, where its statutory requirements are satisfied.

The accountability framework should address:

Lawful processing.

Appropriate notice and consent where applicable.

Security safeguards.

Data fiduciary responsibilities.

Individual rights under the applicable statutory provisions.

Breach response and accountability.

A distinction must be maintained between biological samples, raw genomic sequences and digital personal data. They are related but are not necessarily governed identically.

C. Medical negligence

Where a biomarker test is improperly performed or interpreted, liability may arise under medical negligence principles.

A claimant would generally need to establish the applicable duty, breach, causation and legally recognised damage.

Not every incorrect biomarker result automatically establishes negligence. Scientific uncertainty, accepted professional practice and the circumstances of the test must be considered.

4. Important Judicial Decisions and Case Laws

The following decisions provide the principal legal foundations for developing Continuous Biomarker Accountability. Some concern general medical negligence and privacy rather than biomarkers directly.

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

Indian Supreme Court

Facts: The case concerned the constitutional validity of privacy-related issues arising from the Aadhaar identification framework.

Judgment: The nine-judge Constitution Bench recognised privacy as a fundamental right protected under Article 21 and other constitutional freedoms.

Relevance to biomarker accountability:

The judgment provides a constitutional foundation for protecting genetic, molecular and other health-related information.

Continuous biomarker systems may generate highly detailed personal health profiles. Their collection, processing and sharing therefore raise questions of informational privacy, autonomy and proportionality.

Legal principle: Health-related biological information must be governed consistently with constitutional privacy and dignity.

Indian Kanoon+1

2. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Indian Supreme Court

Facts: A patient consented to a diagnostic procedure, but the doctor performed additional surgical procedures without obtaining the required consent.

Judgment: The Supreme Court explained the requirements of valid medical consent, including voluntariness, competence and adequate information.

Relevance to biomarker accountability:

A patient's consent to one biomarker test should not automatically be treated as consent to every subsequent use of the biological sample or resulting information.

For example, consent to cancer biomarker testing does not necessarily authorise:

Unrelated genetic research.

Commercial exploitation of biological material.

Unrestricted sharing with pharmaceutical companies.

Additional testing for unrelated conditions.

Indefinite secondary use without an appropriate legal basis.

Legal principle: Medical consent must be appropriate to the nature and purpose of the proposed intervention.

Indian Kanoon+1

3. Kusum Sharma v. Batra Hospital & Medical Research Centre (2010) 3 SCC 480

Facts: The Supreme Court considered the principles governing allegations of medical negligence.

Judgment: The Court explained that medical professionals must exercise reasonable skill, knowledge and care. A doctor is not automatically negligent merely because another professional might have adopted a different approach.

Relevance to biomarker accountability:

This principle applies when healthcare professionals:

Select a particular biomarker test.

Interpret a complex molecular result.

Decide whether repeat testing is clinically necessary.

Choose a treatment based on biomarker evidence.

Evaluate contradictory laboratory findings.

A physician's failure to monitor a biomarker may constitute negligence where monitoring was reasonably required under the applicable standard of care.

However, a difference of scientific opinion does not by itself establish liability.

Indian Kanoon+1

4. Jacob Mathew v. State of Punjab (2005) 6 SCC 1

Legal significance: The Supreme Court examined the standard for establishing medical negligence and the distinction between an unfortunate medical outcome and actionable professional negligence.

Relevance:

A biomarker-based treatment failure should not automatically result in professional liability.

The court must examine whether the healthcare professional failed to exercise the level of competence and care expected from a reasonably competent practitioner in the relevant circumstances.

This is particularly important in precision medicine, where biomarker interpretation may involve evolving scientific evidence.

5. Moore v. Regents of the University of California (1990) 51 Cal. 3d 120

Jurisdiction: United States.

Facts: John Moore's biological cells were used in commercially valuable research without his informed knowledge of the researchers' financial interests.

Judgment: The California Supreme Court rejected his conversion claim concerning ownership of the excised cells but allowed claims based on breach of fiduciary duty and failure to disclose material financial interests to proceed.

Relevance to biomarker accountability:

The decision is important for determining the responsibilities of researchers who obtain biological samples for scientific and commercial purposes.

It highlights the importance of:

Disclosure of commercial interests.

Transparency in biomedical research.

Appropriate informed consent.

Researcher accountability.

Protection against undisclosed conflicts of interest.

Legal principle: Biomedical research involving human biological material raises disclosure and fiduciary questions even where property ownership claims are not recognised.

Justia Law

6. Greenberg v. Miami Children's Hospital Research Institute 264 F. Supp. 2d 1064 (S.D. Fla. 2003)

Facts: Families affected by Canavan disease contributed biological materials and research assistance towards identifying the disease-associated gene. The researchers subsequently developed commercial genetic testing.

Judgment: The court considered claims involving informed consent, fiduciary obligations and the use of contributed research materials. It rejected the plaintiffs' unjust-enrichment and conversion theories on the facts.

Relevance:

The case illustrates the legal tensions between patient participation, genetic research, commercial development and disclosure.

It is relevant to continuous biomarker governance because biomarker information may be reused in research and commercial diagnostic development.

Legal principle: Research participation does not automatically resolve every question concerning the permissible use and commercial development of contributed biological information.

PubMed

7. Montgomery v. Lanarkshire Health Board [2015] UKSC 11

Facts: A pregnant patient was not adequately informed about a material risk associated with vaginal delivery and the alternative of caesarean delivery.

Judgment: The UK Supreme Court emphasised the patient's right to be informed of material risks and reasonable alternatives.

Relevance:

Biomarker-based clinical decisions may involve material uncertainties, limitations and treatment alternatives.

A patient should receive appropriate information about the clinical significance of a biomarker and the consequences of relying upon it when that information is material to the treatment decision.

Legal principle: Medical disclosure must respect patient autonomy and material treatment risks.

8. Williams v. Quest/Athena – Genetic Testing Litigation

Jurisdiction: United States.

Background: Litigation arose after a genetic variant associated with a serious inherited condition was initially classified as a variant of uncertain significance and later regarded as pathogenic.

Relevance:

The dispute illustrates the potential consequences of changing genetic interpretations and questions concerning the responsibilities of laboratories and clinicians.

It is important to distinguish this litigation from a final appellate precedent establishing a general duty to continuously reinterpret genetic results.

The broader legal question is whether a laboratory that becomes aware of a clinically significant reinterpretation should notify the ordering physician and whether the physician should communicate that information to the patient.

PubMed Central (PMC)+1

9. Cases concerning the duty to recontact former patients

The developing literature on genetic testing discusses whether healthcare professionals must contact former patients when scientific knowledge changes the interpretation of earlier results.

The important distinction is between:

A duty to correct an originally negligent diagnosis.

A duty to communicate newly discovered risks during ongoing treatment.

A duty to undertake fresh reinterpretation of an old test.

A duty to contact a former patient following a scientifically justified reclassification.

There is no universally established general legal duty to periodically reinterpret all historical genomic results or recontact every former patient.

However, reasonable efforts to communicate a material updated result may be ethically and potentially legally important, particularly where the information could materially change medical treatment.

PubMed+2

5. Allocation of Legal Responsibility

Continuous Biomarker Accountability requires a clear distribution of responsibilities.

An institution should not escape its own legal obligations merely by transferring a biomarker dataset to another organisation.

6. Major Areas of Legal Liability

A. Diagnostic negligence

A laboratory may face liability if it negligently performs a test, misidentifies a biomarker or reports an inaccurate result.

B. Failure to monitor

A physician or hospital may face liability where clinically necessary monitoring is omitted and that omission causes foreseeable harm.

C. Failure to communicate updated findings

A significant reinterpretation may create a duty to communicate, depending on the continuing treatment relationship, applicable professional standards and the circumstances.

D. Unauthorised secondary use

Using biomarker information for unrelated research or commercial purposes without an appropriate legal basis may raise consent, privacy and data-protection issues.

E. Algorithmic discrimination

Automated systems may use biomarker information to determine treatment eligibility or assess disease risks.

Potential legal concerns include:

Unfair treatment decisions.

Inaccurate risk classification.

Discriminatory profiling.

Lack of transparency.

Inadequate human oversight.

F. Product liability

Where an in-vitro diagnostic device or biomarker-based medical product is defective, applicable medical-device and product-liability provisions may become relevant.

7. Hypothetical Legal Case Study

Consider the following situation.

A patient undergoes genetic testing for hereditary cancer susceptibility. The laboratory initially classifies a particular genetic variant as uncertain.

Five years later, new scientific evidence establishes that the variant is pathogenic.

The laboratory updates its internal classification but does not communicate the revised result to the treating hospital. The patient subsequently develops cancer that might have been detected or managed earlier through appropriate surveillance.

The following legal questions arise:

Did the laboratory have an obligation to review or update its earlier interpretation?

Did the laboratory have a duty to notify the ordering physician?

Did the physician remain in an ongoing professional relationship with the patient?

Would a reasonably competent physician have taken steps to communicate the revised result?

Could earlier communication have prevented or reduced the harm?

Was the patient adequately informed about the possibility of future reinterpretation?

Possible legal consequences:

Medical negligence proceedings.

Consumer protection claims.

Claims involving breach of confidentiality.

Regulatory investigation.

Institutional liability.

Compensation where legally established elements of liability are satisfied.

The outcome would depend on evidence of duty, breach, causation and damage, rather than merely the fact that scientific knowledge changed.

8. Institutional Compliance and Accountability Model

A healthcare institution implementing continuous biomarker accountability should establish the following safeguards.

Continuous Biomarker Accountability Framework

Pre-testing consent

Explain the purpose of testing, possible secondary uses, limitations and arrangements for future communication.

Scientific validation

Establish laboratory quality assurance, test validation and appropriate reporting standards.

Continuous review

Establish risk-based procedures for identifying clinically significant new findings.

Clinical interpretation

Ensure qualified professionals assess the medical significance of biomarker changes.

Patient notification

Establish documented procedures for communicating material results and attempting to contact affected patients.

Data protection

Maintain access controls, security safeguards, retention policies and appropriate legal authorisation for data use.

Independent audit

Review errors, reporting failures, adverse events and institutional compliance.

9. Critical Legal and Ethical Challenges

Continuous Biomarker Accountability creates several difficult questions for future biomedical law.

1. The problem of perpetual responsibility

Should a laboratory remain responsible for a genetic test for the entire lifetime of the patient?

An unlimited obligation may be impractical. Conversely, ending responsibility immediately after delivering the report may be inappropriate where the institution receives a material update while the clinical relationship continues.

2. Scientific uncertainty

Not every new research finding justifies changing a patient's diagnosis or treatment. Reinterpretation must be scientifically defensible.

3. Family implications

Genetic biomarkers may reveal information about biological relatives. The patient's confidentiality must be balanced against applicable legal and ethical duties concerning significant familial risks.

4. Commercial exploitation

The commercial value of biomarker datasets raises questions about consent, transparency, financial conflicts and permissible secondary use.

5. Artificial intelligence

AI-based biomarker monitoring creates questions about responsibility when a system fails to identify a significant biological change.

Responsibility may involve the software developer, laboratory, healthcare institution and treating professional, depending on their respective roles and legal duties.

6. Patient autonomy

Continuous monitoring must not become compulsory biological surveillance. Patients should retain appropriate control over medical decisions, subject to applicable legal exceptions.

10. Suggested Principles for Future Legal Development

A specialised Continuous Biomarker Accountability framework could be developed around eight principles:

Scientific Reliability Principle: Biomarker testing must follow appropriate scientific standards.

Informed Consent Principle: Patients must understand the purpose and material implications of testing.

Continuing Review Principle: Material scientific developments should be assessed through appropriate review mechanisms.

Recontact Principle: Significant clinically actionable reinterpretations should trigger reasonable notification procedures where appropriate.

Data Integrity Principle: Biomarker information must remain accurate, secure and traceable.

Clinical Responsibility Principle: Automated results must not eliminate appropriate professional oversight.

Non-Discrimination Principle: Biomarker information should not become a basis for unlawful discrimination.

Remedial Accountability Principle: Institutions must provide effective mechanisms for correcting errors and addressing legally established harm.

These principles could inform future legislation, professional standards and institutional protocols. They should not be mistaken for eight independently enforceable statutory duties under current Indian law.

11. Conclusion

Continuous Biomarker Accountability represents an important development in the relationship between biomedical science and legal responsibility.

Traditional medical accountability often focuses on a particular diagnostic procedure, clinical decision or treatment. Biomarker-driven medicine creates a more complex situation because biological information may be repeatedly measured, reinterpreted and used in subsequent healthcare decisions.

The constitutional privacy principles in Justice K.S. Puttaswamy, informed-consent principles in Samira Kohli, and professional negligence standards in Kusum Sharma provide important foundations for developing this framework in India.

Comparative decisions such as Moore and Greenberg further demonstrate the importance of transparency, research ethics and responsible use of biological materials.

The central proposition is that biomedical accountability should extend beyond the production of a biomarker result to the responsible governance of its subsequent interpretation, communication and clinical application.

Although there is not yet a universally recognised independent doctrine of Continuous Biomarker Accountability, its principles offer a substantial foundation for future developments in medical negligence law, biotechnology regulation, genetic privacy and precision-medicine governance.

12. Important Research References

For further academic research:

Physicians' Duty to Recontact and Update Genetic Advice (2018). Read research article.

Does the Law Require Reinterpretation and Return of Revised Genomic Results? (2021). Read research article.

Cases in Precision Medicine: Is There an Obligation to Return Reinterpreted Genetic Results to Former Patients? (2023). Read research article.

Ethical, Legal, and Policy Dimensions and Contentions for Reanalysis and Reinterpretation of Clinical Genetic Testing Results (2025). Read research article.

ACMG, Patient Re-contact After Revision of Genomic Test Results. Read professional guidance.

Which direction should the next expansion take?

PhD-level Indian legal analysis International comparative case laws Future regulatory doctrine